NIH May Grant Licenses to Produce Anthrax Vaccine
The federal agency’s notice announced it may grant exclusive licenses to utilize five inventions whose patent rights have been assigned to the United States of America.
The National Institutes of Health announced that it may grant of an exclusive license to practice the inventions in several patent applications involving anthrax vaccines to Biologics Resources LLC, which is located in Boyds, Md. The patent rights in the inventions have been assigned to the United States of America.
The listed patent applications are:
- E-146-2004/0, Purcell et al., "`Monoclonal Antibodies That Neutralize Anthrax Protective Antigen (PA) Toxin," U.S. Patent Application Number 60/639,074, filed on Dec. 22, 2004, PCT Application Number PCT/US2005/046/790, filed on Dec. 21, 2005, and U.S. Patent Application Number
11/793,735, filed on Dec. 8, 2009
- E-123-2007/0, Purcell et al., "Monoclonal Antibodies that Neutralize B. anthracis Protective
Antigen (PA), Lethal Factor (LF) and Edema Factor (EF)," U.S. Patent Application Number 60/903,022, filed on Feb. 23, 2007, PCT Application Number PCT/US2008/054609, filed on Feb. 21, 2008, and
U.S. Patent Application Number 12/528,427, filed on Aug. 24, 2009, and European Patent Application Number 08730415.0, filed on Sept. 23, 2009
- E-125-2008/0, Purcell et al., "Monoclonal Antibodies That React With the Capsule of Bacillus anthracis," U.S. Patent Application Number 61/116,222, filed on Nov. 19, 2008, PCT Application Number PCT/US2009/065198, filed on Nov. 19, 2009, and U.S. Patent Application Number 13/130,044, filed on May 18, 2011
- E-343-2002/0, Schneerson et al., "gammaPGA Conjugates for Eliciting Immune Responses Directed Against Bacillus anthracis and Other Bacilli," U.S. Patent Application Number 60/476,598, filed on June 5, 2003, PCT Application Number PCT/US2004/17736, filed on June 4, 2004, U.S. Patent Application Number 10/559,825, filed Dec. 2, 2005, now U.S. Patent Number 7,803,386, European Patent Application Number 04754360.8, filed June 4, 2004, Canadian Patent Application Number 2,528,067, filed June 4, 2004, and Australian Patent Application Number 2004252091, filed June 4, 2004, now Australian Patent Number 2004252091
- E-040-2005/0, Schneerson et al., "Methods for Preparing Immunogenic Conjugates," U.S. Patent Application Number 11/005,851, filed on Dec. 6, 2004, now U.S. Patent Number 7,625,736, PCT Application Number PCT/US2005/19678, filed June 3, 2005, European Patent Application Number 05758048.2, filed June 3, 2005, now European Patent Number 1765394 (rights were validated in Germany (Patent Number 602005015855), France (Patent Number 1765394), Great Britain (Patent Number 1765394), and Ireland (Patent Number 1765394)), Indian Patent Application Number 7703/DELNP/2006, filed June 3, 2005, Chinese Patent Application Number 200580018108.2, filed June 3, 2005, Australian Patent Application Number 2005249571, filed June 3, 2005, now Australian Patent Number 2005249571, Canadian Patent Application Number 2,568,364, filed June 3, 2005, and U.S. Patent Application Number 12/582,420, filed Oct. 20, 2009
NIH is accepting written comments and/or application for a license if received by Sept. 26. Send requests for a copy of the patent application, or inquiries, comments, and other materials relating to the contemplated license, to: Peter Soukas, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; e-mail firstname.lastname@example.org; phone 301-435-4646; fax 301-402-0220.
The purpose of the license is prevention and/or therapy of B. anthracis (anthrax) infection by immunization with conjugate vaccines against anthrax and/or passive immunization with monoclonal antibodies against B. anthracis.